Title: Psilocybin services and mental health outcomes within Oregon's state-regulated model

Authors: Amanda Gow, MS,[1] Emily Shih PhD,[2] Ryan Reid, BS,[1] Jimmy J. Qian, MS,[2] Charan Mellor, MA,[1] Lynne Alison McInnes, MD,[2] Robin Carhart-Harris, PhD,[3] Jennie N. Davis, PhD[1,4*]

Affiliations:

1. Bendable Therapy, Bend, Oregon
2. Osmind, San Francisco, California
3. Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California
4. Center for Health Systems Effectiveness, Oregon Health & Science University

***Corresponding Author:** Jennie N. Davis, Bendable Therapy, jdavis@bendabletherapy.org

Abstract

Importance: In 2020, Oregon became the first U.S. state to establish a regulated framework for adults to access supervised psilocybin services using naturally derived mushroom products. No studies have examined mental health outcomes among individuals receiving psilocybin in this context.

Objectives: To evaluate changes in self-reported symptoms of depression, anxiety, and well-being 30-days following a psilocybin session under the Oregon state-regulated model, and document session-related adverse events and psilocybin doses consumed.

Design: A prospective, naturalistic study (March 2024-April 2025) where online surveys were completed pre-session, 1-day, and 30-days post-psilocybin session.

Setting: Oregon psilocybin services program.

Participants: A convenience sample of adults 21 years or older participating in a psilocybin services program: n=126 invited; n=91 enrolled.

Exposure: Legal psilocybin session.

Main Outcomes and Measures: Surveys collected demographics and medical and mental health histories (pre-session); self-reported depression, anxiety, and well-being symptoms (pre-session, 30-days post-session); and adverse events (e.g., hallucinogen persisting perception disorder [HPPD]; 1-day and 30-days post-session). Main outcomes were symptoms of depression (Patient Health Questionnaire-8), anxiety (Generalized Anxiety Disorder-7), and well-being (World Health Organization Well-Being Index). Change in symptoms over time was evaluated using linear mixed-effects models with timepoint as the random effect and fixed effects of sex (male/female), concurrent psychiatric medication use (yes/no), age, and session dose (total psilocybin equivalents [TPE, mg]: psilocybin mg + 1.39 * psilocin mg).

Results: Participants (n=88) were 43 (22,79) years (median, range), male (52.0%), predominantly from Oregon (53.4%), psychedelic experienced (64.8%), and concurrently using

psychiatric medication (46.6%). Pre-session, 69.2% reported mild-to-severe depression, 67.0% mild-to-severe anxiety, and 93.2% low or very low well-being. Significant improvements were observed across all outcome measures 30-days post-session ($p<0.001$), including in a stratified sensitivity analysis by concurrent psychiatric medication usage ($p<0.001$, all measures in both groups). Average session dose was 27.8 mg (8.2 SD) TPE. Two participants (2.3%) reported symptoms consistent with HPPD at 1-day post-session, but none at 30-days post-session.

Conclusions and Relevance: Psilocybin sessions delivered under the Oregon regulatory model were associated with clinically meaningful improvements in depression, anxiety, and well-being 30-days post-session. As other U.S. jurisdictions explore similar models, this initial real-world evidence supports the therapeutic effectiveness of legal psilocybin services.

36 **Introduction**

37 Psilocybin has emerged as a promising therapeutic intervention for mental health
38 disorders, including depression and anxiety.[1–6] As a naturally occurring psychoactive alkaloid
39 found in certain species of mushrooms, once ingested, psilocybin is converted to psilocin to
40 produce its characteristic psychedelic effects by acting on serotonin receptors (e.g., 5-$HT2_A$).[7]
41 These neuropharmacological actions are thought to underlie the improvements in mental health
42 symptoms observed across controlled clinical trials and naturalistic observational studies.[4–6,8–17]

43 Most psilocybin clinical trials enroll highly selective samples under tightly controlled
44 conditions, typically excluding individuals with complex psychiatric diagnoses or active
45 psychiatric medication use, and administering synthetic psilocybin within standardized dosing
46 protocols.[4,8–12] Only one trial has used a natural mushroom formulation to examine impacts of
47 psilocybin on alcohol use disorder, with findings highlighting the therapeutic potential of natural
48 mushroom formulations.[18] Naturalistic studies introduce greater variability in participants'
49 medical and psychiatric histories, session formats, and psilocybin source (often whole fruit
50 mushrooms), yet still demonstrate improvements in depression, anxiety, and well-being[13–
51 15,17,19,20] However, additional research bridging controlled clinical efficacy trials and real-world
52 effectiveness is needed to understand psilocybin's mental health benefits in diverse,
53 community-based populations.

54 In 2020, Oregon voters approved Measure 109, establishing the first regulated
55 psilocybin services model in the United States and globally. These services are administered by
56 the Oregon Health Authority (OHA) through its Oregon Psilocybin Services (OPS) section.[21]
57 Oregon's non-medical model permits adults 21 years and older to access psilocybin by
58 consuming products derived from whole fruit mushrooms (*Psilocybe cubensis*) at licensed
59 service centers under the supervision of licensed facilitators.[22] The model does not require a
60 medical diagnosis, prescription, or clinical referral, despite mental health applications being
61 common reasons for psilocybin use.[1] In 2025, statewide aggregate data released under Senate

62 Bill 303 began providing basic information, including demographics, psilocybin dosages, and
63 session types. However, these data do not include clinical outcomes or follow-up assessments,
64 limiting insight into the model's therapeutic effectiveness.

65 To address this gap, this study aimed to evaluate changes in self-reported symptoms of
66 depression, anxiety, and well-being following a psilocybin session under Oregon's regulated
67 model, and document session-related adverse events and psilocybin doses consumed.
68 Predictors of session dosage were additionally explored to understand potential correlates of
69 dosing decisions (e.g., participant characteristics, mental health history). Characterizing who
70 uses psilocybin services and with what outcomes is critical to understanding the benefits and
71 limitations of Oregon's regulated framework.

72 **Methods**

73 **Setting and Participants**

74 This prospective, naturalistic study (March 2024-April 2025) was integrated into an
75 existing Oregon legal psilocybin services program at Bendable Therapy ("Bendable") which
76 enhanced the Oregon requirements[21] by including additional screening and support sessions
77 **(Figure 1)**. Individuals were invited to the study and to complete the informed consent at a
78 virtual interview if they met Oregon's and Bendable's eligibility criteria: aged ⩾21 years, no
79 lithium use in the past 30 days (due to seizure risk[23]), no active psychosis, no active suicidal or
80 homicidal ideation, not pregnant or breastfeeding (Bendable only). No compensation was
81 provided. WCG Institutional Review Board approved this study.

82 **Procedures and measures**

83 A pre-session screening application (completed on average 75 days prior to the
84 psilocybin administration session) collected demographics, medical, mental health, psychedelic
85 use histories, medication usage, and validated scales assessing self-reported symptoms of

86 depression (Patient Health Questionnaire, PHQ-9[24]), anxiety (Generalized Anxiety Disorder,
87 GAD-7[25]), and well-being (World Health Organization Well-Being Index, WHO-5[26]) over the past
88 2 weeks (Figure 1). The PHQ-9 was modified to PHQ-8 by excluding the suicidal ideation item;
89 scores were adjusted accordingly.[27] On the administration session day, before consuming
90 psilocybin, participants completed the Imperial Psychedelic Predictor Scale (iPPS).[28] Consumed
91 psilocybin and psilocin doses (mg) were recorded. Additional tool and measure details are in
92 **Supplemental Material and eTable 1**.
93 A survey emailed to participants 30-days post-session (completed on average 34 days
94 post-session) included follow-up PHQ-8, GAD-7, and WHO-5 assessments, integration session
95 attendance, and collected information on adverse events by assessing lingering unpleasant
96 psychological effects attributed to the psilocybin session (i.e., anxiety, existential struggle, social
97 disconnection, depersonalization/derealization),[29] and assessing symptoms of Hallucinogen
98 Persisting Perception Disorder (HPPD),[30] a condition of enduring, distressing visual perceptions
99 after psychoactive substance intake[29] (also assessed in a survey sent 1-day post-session)
100 (Figure 1). For participants completing two sessions within the follow-up period (e.g., weeklong
101 retreats), data were collected according to the first session only. Online assessment were
102 completed via Jotform (Jotform Inc.).
103 Participants completed individual or group facilitator-supervised psilocybin sessions at
104 licensed service centers following Oregon regulations,[21] and Bendable's protocols were not
105 altered for this study. Psilocybin was consumed as whole mushrooms or tea made with ground
106 whole mushrooms. Session dosing followed Bendable's protocol of 20-30 mg psilocybin
107 including optional 'booster doses' (offered approximately 1-hr after initial dose). Per Oregon
108 rules participants may request lower or higher doses, up to a maximum of 50 mg.[31,32]
109 **Statistical analysis**
110 Pre-session characteristics of participants are presented as medians (range) or
111 frequencies (proportions). Primary outcomes were change in mental health status from pre-

112 session to 30-days post-session using the PHQ-8, GAD-7, and WHO-5 scales. Clinically
113 significant depression and anxiety were defined as scores >10, and poor well-being as scores
114 <13 (Supplemental Material).

115 Per Oregon regulations, mushrooms were grown, processed, and potency-tested for
116 analyte content (psilocybin and psilocin) in Oregon licensed facilities; product packaging listed
117 analyte content in milligrams per gram of whole mushroom.[32] Oregon regulations define dose by
118 psilocybin content; because psilocybin rapidly converts to its pharmacologically active form of
119 psilocin once ingested,[7] Bendable calculates dose as Total Psilocybin Equivalents (TPE =
120 psilocybin mg + 1.39 × psilocin mg), a metric assuming complete conversion of psilocybin to
121 psilocin based on molecular weight.[33] We report both TPE and psilocybin dose.

122 We used separate linear mixed effects models to evaluate changes in outcomes across
123 two timepoints (means, SE). Timepoint was modeled as a categorical variable (pre-session as
124 reference), with birth sex (male/female), age (years), concurrent psychiatric medication use
125 (yes/no), and dose (TPE, mg) included as fixed effects. Participant-level random intercepts and
126 slopes accounted for individual differences in pre-session symptom levels and change over
127 time. Effect sizes 30-days post session (relative to pre-session) were calculated using Cohen's
128 *d*, and classified as small (0.20-0.49), moderate (0.50-0.79), large ($\geq$0.80), or very large ($\geq$1.2).[34]
129 A post-hoc simulation-based power analysis (α=0.05) indicated approximately 100% power for
130 large effects and 89% for small effects.

131 *Sensitivity and exploratory analyses*

132 In a sensitivity analysis, we repeated the adjusted models substituting TPE with
133 psilocybin dosage to assess robustness to an alternative dose specification. In a second
134 analysis to assess whether findings were driven by participants with additional dosing, we
135 restricted the sample to participants who completed a single session during the study period
136 (n=75), excluding those with multiple sessions (n=13). In a third analysis, we stratified the
137 sample by concurrent psychiatric medication use and repeated the adjusted models separately

among participants with (n=41) and without (n=47) pharmacotherapy to descriptively assess whether patterns of outcomes were consistent across medication status.

To explore correlates of dosing decisions, we used univariate linear regression models to examine predictors of session dose (TPE). Predictors included pre-session PHQ-8, GAD-7, and WHO-5 scores; age; birth sex; most commonly reported diagnoses: depression, anxiety, post-traumatic stress disorder (PTSD); concurrent psychiatric medication use; and prior psychedelic experience.[14] In a separate multivariate regression model, iPPS subscales were entered simultaneously to assess their independent contributions to TPE. Given these analyses' exploratory nature, p-values were not adjusted for multiple comparisons.

Analyses were conducted using R/R Studio version 4.4.2 (R Foundation), and included only participants who completed pre- and post-session surveys (n=3 excluded); we set statistical significance at $p<0.05$.

Results

Participant demographics, mental health history and psychedelic experience

During the study period, n=311 screening applications were received. Of these, n=126 individuals met psilocybin services' eligibility criteria and were invited to participate, n=91 enrolled, and n=88 completed all study components. Participants (n=88) ranged in age from 22-79 years (median: 43 years), were approximately balanced by birth sex and gender identity (52.0% male; 50.0% male-identifying), and were predominantly White (87.5%), educated (84.1% with higher education), and employed (67.1%), with only 22.7% reporting annual household income below $50,000 **(Table 1)**. Most participants lived in Oregon (53.4%) and 15.9% were military veterans. Depression (51.1%), anxiety (42.0%), and PTSD (19.3%) were the most reported mental health diagnoses. Almost half (46.6%) reported concurrent use of psychiatric medications (medication type and dosage were not systematically collected) and participation in therapy (56.8%). The majority (64.8%) had prior psychedelic experience, and cost was the most frequently reported barrier to seeking psilocybin services (46.6%) (Table 1).

164 Most participants completed individual sessions (56.8%) rather than group sessions (43.2%),
165 and 80.0% completed at least one integration session during follow-up.

166 *Mental health outcomes after a psilocybin session*

167 We examined whether participation in a psilocybin session was associated with changes
168 in mental health outcomes. Pre-session, 69.2% of participants reported mild to severe
169 depression symptoms, 67.0% reported mild to severe anxiety symptoms, and 93.2% reported
170 low or very-low sense of well-being, reflecting clinically significant symptom levels across all
171 measures **(Table 2)**. At approximately 30-days post-session, improvements were observed
172 across all measures, with 61.4% of participants reporting minimal depression, 70.5% reporting
173 minimal anxiety, and 64.8% reporting normal levels of well-being.

174 Modeling results similarly reflected significant improvements in mental health outcomes
175 over time (**Figure 2**, **eTable 2 in Supplement)**. PHQ-8 and GAD-7 mean scores significantly
176 decreased pre-session to 30-days post-session, suggesting robust declines in depression and
177 anxiety symptoms: PHQ-8 score change of -4.63 (0.57 SE) points; $p<0.001$; $d=0.90$ (95% CI:
178 0.68, 1.12) large; GAD-7 score change of -4.85 (0.57) points; $p<0.001$; $d=1.04$ (0.80, 1.17)
179 large. WHO-5 well-being scores also improved at follow-up with a score change of +10.67
180 (0.59) points; $p<0.001$; $d=-2.14$ (-2.38, -1.90) very large), indicating significant gains in well-
181 being. Of the covariates examined, only concurrent psychiatric medication use was positively
182 associated with post-session PHQ-8 scores ($p=0.040$).

183 Sensitivity analyses, one substituting psilocybin for TPE as the dose covariate in all
184 outcomes models and another limited to participants who completed a single administration
185 session (n=75), yielded results consistent with the primary analysis, with no change in the
186 direction or magnitude of timepoint effects. In a third sensitivity analysis, results from stratified
187 models by concurrent psychiatric medication use were largely consistent with those from the full
188 cohort, with significant post-session improvement across all outcomes observed in both groups

189 (p<0.001). Overall, these findings support the robustness of the primary results **(eTables 3-5 in**
190 **Supplement).**

191 *Post-session adverse events*

192 Participants (n=35, 39.7%) reported symptoms of HPPD at 1-day post-session, and two
193 (2.3%) indicated these symptoms caused significant distress and were attributed to the
194 psilocybin session, potentially meeting diagnostic HPPD criteria. Fewer participants (n=16,
195 18.2%) reported HPPD symptoms at 30-days post-session, with none reporting the symptoms
196 caused significant distress. Three (3.4%) participants reported lingering negative effects of the
197 psilocybin experience, noting increased feelings of anxiety or fear, existential struggle, social
198 disconnections, and difficulty coping with family members.

199 *Session dose and exploratory analyses predicting psilocybin session dose*

200 The average dose (TPE) consumed by participants was 27.8 mg (8.2 SD), and was 24.3
201 mg (8.3 SD) when restricted to psilocybin **(Table 3).** In exploratory analyses examining
202 predictors of dose (TPE), the only significant predictor was concurrent use of psychiatric
203 medications, which was associated with greater administered dose (b=3.44, p<0.05, **eTable 6**
204 **in Supplement)**; these participants received an average dose of 29.6 mg TPE (26.2 mg TPE for
205 those not taking psychiatric medications). No iPPS subscales were significantly associated with
206 dose (**eTable 7 in Supplement**).

207 **Discussion**

208 This prospective, naturalistic study presents the first results examining the impact of
209 psilocybin on mental health outcomes within Oregon's state-regulated model. We found that at
210 30-days post-psilocybin session, participants reported significant reductions in depression and
211 anxiety symptoms and significant improvements in well-being. These benefits were observed in
212 a community-based population that included individuals with multiple psychiatric diagnoses and
213 those actively using psychiatric medications, populations often excluded from research of
214 psilocybin's impact on mental health. Our findings suggest that psilocybin services delivered

215 within a structured and supportive framework can produce therapeutic benefits. This
216 translational evidence is needed to inform policy and clinical implementation as jurisdictions
217 worldwide consider regulated psilocybin programs.

218 As a therapeutic intervention, psilocybin is particularly effective when combined with
219 therapeutic support,[1–4] though therapeutic support is not uniformly included in studies of
220 psilocybin's impact on mental health.[1] The results of this study were achieved under Bendable's
221 enhanced, supportive model relative to the minimum requirements set forth under Oregon's
222 Measure 109 through incorporating comprehensive screening, multiple preparation sessions,
223 and structured integration support with licensed facilitators of which many held additional clinical
224 health licenses. Such enhancements potentially influenced the overall significant improvements
225 in mental health outcomes among study participants, including limited adverse events and few
226 reports of psychedelic harm, which is consistent with prior studies.[35] Research also indicates
227 that integrative psychological support and facilitated processing after psychedelic-assisted
228 sessions increase the likelihood of sustained benefits.[36,37]

229 Study participants demonstrated clinically significant improvements in self-reported
230 symptoms of depression, anxiety, and well-being. At 30-days post-session, 65% of participants
231 reported normal well-being despite approximately one-third continuing to report mild to severe
232 symptoms of depression or anxiety. Because the WHO-5 Well-Being Index captures mental and
233 emotional domains related to psychological flexibility and adaptive functioning,[26] these findings
234 may suggest a growing capacity for change and emerging emotional resilience, which are
235 domains of functioning that individuals may particularly value.[38] Other studies of the impacts of
236 psilocybin on well-being likewise reported increased well-being or life satisfaction post-
237 psilocybin session.[39]

238 Consistent with our results, a recent naturalistic study of U.S. veterans attending
239 psychedelic retreats outside the U.S. documented clinically significant reductions in depression
240 with the PHQ-9 one-month post-psychedelic session, though not all participants consumed

241 psilocybin as the psychedelic substance (some received ayahuasca).[13] A naturalistic study from
242 Germany similarly reported significant improvements in depression (PHQ-9) and anxiety (GAD-
243 7) symptoms following a psilocybin session, with an approximate 25 mg psilocybin dose from
244 fresh mushrooms, though follow-up timepoints were at 1 week and 3 months.[14] This study
245 included participants with multiple psychiatric diagnosis, which is less common in clinical
246 trials.[40,41] In our study, nearly two-thirds of participants had mental health diagnoses, many
247 concomitant, and few experienced post-session adverse events, adding to the extant evidence
248 that psilocybin services can be safely delivered to populations experiencing a range of mental
249 health conditions in real-world settings.

250 In clinical trials, dose is standardized and often fixed at 25 mg of synthetic
251 psilocybin,[5,8,40,42,43] including the recent COMPASS Pathways Phase 3 COMP005 trial (25).[16]
252 The average doses administered in our study (27.8 mg TPE, 24.3 mg psilocybin) were
253 comparable to trials' standard dose, and outcomes were similar whether assessed by TPE or
254 psilocybin content alone. The novel dosing protocol described in our study, which accounts for
255 both psilocybin and psilocin content, provides a useful framework for other states developing
256 regulated programs utilizing natural-derived mushroom products, and may inform policy
257 decisions regarding maximum dose limits. While Oregon's legal maximum is 50 mg, this study
258 demonstrated meaningful improvements in outcomes with limited adverse events at an average
259 dose below 30 mg TPE, suggesting that lower doses may be both effective and well-tolerated in
260 real-world settings. Additional research is needed to confirm both safety and efficacy of this
261 dosing practice, and among a greater diversity of populations than was included in this study.

262 Individuals taking psychiatric medications are often excluded from clinical trials to reduce
263 the risk of a psilocybin blunting effect, allow for uniform dosing, and minimize the risk of
264 serotonin toxicity.[33,44] Two psilocybin clinical trials have examined the impacts on participants
265 taking psychiatric medications, and found reduced depressive symptoms[42] and reduced adverse
266 effects of psilocybin.[45] We found that participants using psychiatric medications consumed

267 modestly higher average doses. Sensitivity analyses restricted to this subgroup yielded results
268 consistent with the main findings, suggesting concurrent psychiatric medication use did not
269 substantially alter treatment response. While this may suggest that psilocybin services using
270 whole-fruit mushroom products may be effective at improving mental health outcomes without
271 requiring psychiatric medication discontinuation, additional controlled research examining
272 psychiatric medications and doses, and explicitly testing moderation effects, is needed.[46]

273 *Strengths and limitations*

274 This study has several notable strengths. It represents the first systematic evaluation of
275 mental health outcomes following psilocybin administration within the first regulated framework
276 in the US, and the first to quantify both psilocybin and psilocin content in administered doses.
277 This real-world study design provides evidence of effectiveness in naturalistic settings with
278 individuals with mental health complexities thereby offering a realistic assessment of treatment
279 benefits that complement traditional efficacy data.[47] Rigorous data collection and participant
280 follow-up yielded near-complete retention, with data from only three participants excluded.
281 Within-person pre–post assessments reduced between-person confounding, and the use of
282 widely implemented validated instruments for depression, anxiety, and well-being supports
283 comparison with prior studies.

284 Limitations of the study include its small sample size and the predominance of
285 participants residing in Oregon, impacting its generalizability. However, the study was
286 adequately powered to detect medium to large effect sizes in change in mental health
287 symptoms, supporting the robustness of the observed results. As an observational study without
288 a control group, causality cannot be inferred, and placebo effects, self-selection bias,
289 expectancy bias, and unmeasured confounding factors (such as influential participant lifestyle or
290 situational changes during the study period) cannot be ruled out. Also, the follow-up period was
291 limited to 30-days post-session; although this duration aligns with many clinical trials and

observational studies,[4,10,13,40] longer-term effects remain to be determined and should be investigated in future studies conducted within Oregon's regulated model.

Conclusion

In this prospective, naturalistic study, we found that carefully screened participants who underwent a supervised psilocybin session within Oregon's regulated framework and consumed naturally-derived mushroom products experienced significant improvements in depression, anxiety, and overall well-being with few adverse events, even among those with concurrent use of psychiatric medications and complex mental health histories. These findings demonstrate that psilocybin can be delivered safely and effectively in real-world settings, broadening the potential accessibility of psilocybin services as a tool to bridge clinical and community care. For Oregon, these data strengthen confidence in the state's pioneering regulatory framework, offering data-driven guidance for establishing standardized practices in supportive psilocybin service frameworks, while advancing policy goals to safely expand this emerging mental health field.

Acknowledgements

Author Contributions: A.G., R.R. J.J.Q, L.A.A., R.C.H, and J.N.D. designed the study. A.G., R.R., C.M., and J.N.D. collected the data. E.S. conducted data analysis. A.G., E.S., R.R. J.J.Q., and J.N.D. interpreted the data. A.G., E.S., R.R., and J.N.D. wrote the initial draft of the manuscript. All authors critically reviewed the manuscript and approved the final draft. J.N.D. is accountable for all aspects of the study and manuscript.

Funding/Support: This research was financially supported in part by the Jurveston Foundation.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank the participants for their time, trust, and willingness to share their experiences. We also acknowledge the valuable contributions of the Bendable Therapy team members who supported data collection: Brooke Harralson, River Jenkins, Sam Georgi, and Matt Hailey. These individuals did not receive additional compensation for these contributions.

References

1. Dorczok MC, Mittmann G, Ettl T, Steiner-Hofbauer V. Psilocybin-assisted psychotherapy in adults with depression – A literature review. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 2025;142:111508. doi:10.1016/j.pnpbp.2025.111508

2. Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. *The Lancet Psychiatry*. 2016;3(7):619-627. doi:10.1016/S2215-0366(16)30065-7

3. Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. *Psychopharmacology*. 2018;235(2):399-408. doi:10.1007/s00213-017-4771-x

4. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. *J Psychopharmacol*. 2016;30(12):1181-1197. doi:10.1177/0269881116675513

5. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. *New England Journal of Medicine*. 2022;387(18):1637-1648. doi:10.1056/NEJMoa2206443

6. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. *Journal of Affective Disorders*. 2023;327:120-127. doi:10.1016/j.jad.2023.01.108

7. Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of psilocybin. *Addict Biol*. 2002;7(4):357-364. doi:10.1080/1355621021000005937

8. Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for Depression. *New England Journal of Medicine*. 2021;384(15):1402-1411. doi:10.1056/NEJMoa2032994

9. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. *J Psychopharmacol*. 2016;30(12):1165-1180. doi:10.1177/0269881116675512

10. Davis AK, Barrett FS, May DG, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. *JAMA Psychiatry*. 2021;78(5):481-489. doi:10.1001/jamapsychiatry.2020.3285

11. Raison CL, Sanacora G, Woolley J, et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. *JAMA*. 2023;330(9):843-853. doi:10.1001/jama.2023.14530

12. von Rotz R, Schindowski EM, Jungwirth J, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. *eClinicalMedicine*. 2023;56:101809. doi:10.1016/j.eclinm.2022.101809

13. Calnan M, Blest-Hopley G, Busch C, et al. Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings. *Brain and Behavior*. 2025;15(7):e70660. doi:10.1002/brb3.70660

14. Irrmischer M, Puxty D, Yıldırım BO, Deijen JB, Engelbregt H. Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation. *Psychopharmacology (Berl)*. 2025;242(4):725-740. doi:10.1007/s00213-024-06733-3

15. de la Salle S, Kettner H, Thibault Lévesque J, et al. Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy. *Sci Rep*. 2024;14(1):16524. doi:10.1038/s41598-024-66817-0

16. Compass. Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression. Accessed October 12, 2025. https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-First-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx

17. Nygart VA, Pommerencke LM, Haijen E, et al. Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample. *J Psychopharmacol*. 2022;36(8):932-942. doi:10.1177/02698811221101061

18. Jensen ME, Stenbæk DS, Messell CD, et al. Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study. *J Psychopharmacol*. 2025;39(5):463-473. doi:10.1177/02698811251319457

19. Morton E, Sakai K, Ashtari A, Pleet M, Michalak EE, Woolley J. Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of 'magic mushroom' consumption. *J Psychopharmacol*. 2023;37(1):49-60. doi:10.1177/02698811221131997

20. Tap SC, Thomas K, Páleníček T, et al. Concomitant use of antidepressants and classic psychedelics: A scoping review. *J Psychopharmacol*. Published online September 12, 2025:02698811251368360. doi:10.1177/02698811251368360

21. Oregon Health Authority. Oregon Psilocybin Services. Accessed October 11, 2025. https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Pages/Oregon-Psilocybin-Services.aspx

22. Oregon Health Authority. Public Health Division-Chapter 333, Division 333 Psilocybin, Client Information Form. Accessed October 11, 2025. https://secure.sos.state.or.us/oard/viewSingleRule.action?ruleVrsnRsn=319978

23. Nayak SM, Gukasyan N, Barrett FS, Erowid E, Erowid F, Griffiths RR. Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports. *Pharmacopsychiatry*. 2021;54:240-245. doi:10.1055/a-1524-2794

24. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. *J Gen Intern Med*. 2001;16(9):606-613. doi:10.1046/j.1525-1497.2001.016009606.x

25. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med*. 2006;166(10):1092-1097. doi:10.1001/archinte.166.10.1092

26. Topp CW, Østergaard SD, Søndergaard S, Bech P. The WHO-5 Well-Being Index: a systematic review of the literature. *Psychother Psychosom*. 2015;84(3):167-176. doi:10.1159/000376585

27. Shin C, Lee SH, Han KM, Yoon HK, Han C. Comparison of the Usefulness of the PHQ-8 and PHQ-9 for Screening for Major Depressive Disorder: Analysis of Psychiatric Outpatient Data. *Psychiatry Investig*. 2019;16(4):300-305. doi:10.30773/pi.2019.02.01

28. Angyus M, Osborn S, Haijen E, et al. Validation of the imperial psychedelic predictor scale. *Psychol Med*. 54(12):3539-3547. doi:10.1017/S0033291724002204

29. Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. *J Psychopharmacol*. 2022;36(3):258-272. doi:10.1177/02698811211069100

30. Zhou K, de Wied D, Carhart-Harris RL, Kettner H. Prediction of hallucinogen persisting perception disorder and thought disturbance symptoms following psychedelic use. *PNAS Nexus*. 2025;4(4):pgae560. doi:10.1093/pnasnexus/pgae560

31. Oregon Psilocybin Services. Oregon Psilocybin Services: Health and Safety Fact Sheet. Published online May 2025. https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Documents/OPS-Health-and-Safety.pdf

32. Oregon Psilocybin Services. Oregon Psilocybin Services (OPS) Psilocybin Product Potency Information. https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Documents/OPS-Psilocybin-Product-Potency-Information.pdf

33. MacCallum CA, Lo LA, Pistawka CA, Deol JK. Therapeutic use of psilocybin: Practical considerations for dosing and administration. *Front Psychiatry*. 2022;13:1040217. doi:10.3389/fpsyt.2022.1040217

34. Cohen J. Quantitative Methods in Psychology: A power primer. *Psychol Bull*. 1992;112(1):155-159. doi:10.1037//0033-2909.112.1.155

35. Evans J, Aixalà M, Anderson BT, et al. On Minimizing Risk and Harm in the Use of Psychedelics. *Psychiatr Res Clin Pract*. 2025;7(1):4-8. doi:10.1176/appi.prcp.20240128

36. Gorman I, Nielson EM, Molinar A, Cassidy K, Sabbagh J. Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice. *Front Psychol*. 2021;12. doi:10.3389/fpsyg.2021.645246

37. Greń J, Gorman I, Ruban A, Tylš F, Bhatt S, Aixalà M. Call for evidence-based psychedelic integration. *Experimental and Clinical Psychopharmacology*. 2024;32(2):129-135. doi:10.1037/pha0000684

38. Connell J, O'Cathain A, Brazier J. Measuring quality of life in mental health: Are we asking the right questions? *Social Science & Medicine*. 2014;120:12-20. doi:10.1016/j.socscimed.2014.08.026

39. Wiepking L, Bruin E de, Ghiţă A. The potential of psilocybin use to enhance well-being in healthy individuals – A scoping review. Published online November 29, 2023. doi:10.1556/2054.2023.00244

40. Rosenblat JD, Meshkat S, Doyle Z, et al. Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. *Med*. 2024;5(3):190-200.e5. doi:10.1016/j.medj.2024.01.005

41. Aaronson ST, van der Vaart A, Miller T, et al. Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial. *JAMA Psychiatry*. 2024;81(6):555-562. doi:10.1001/jamapsychiatry.2023.4685

42. Goodwin GM, Croal M, Feifel D, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. *Neuropsychopharmacol*. 2023;48(10):1492-1499. doi:10.1038/s41386-023-01648-7

43. Back AL, Freeman-Young TK, Morgan L, et al. Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial. *JAMA Netw Open*. 2024;7(12):e2449026. doi:10.1001/jamanetworkopen.2024.49026

44. Malcolm B, Thomas K. Serotonin toxicity of serotonergic psychedelics. *Psychopharmacology*. 2022;239(6):1881-1891. doi:10.1007/s00213-021-05876-x

45. Becker AM, Holze F, Grandinetti T, et al. Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. *Clin Pharmacol Ther*. 2022;111(4):886-895. doi:10.1002/cpt.2487

46. Erritzoe D, Barba T, Spriggs MJ, Rosas FE, Nutt DJ, Carhart-Harris R. Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression. *J Psychopharmacol*. 2024;38(5):458-470. doi:10.1177/02698811241237870

47. McInnes LA, Marton TF, Qian JJ. Embracing pragmatism for ketamine insurance coverage: Leveraging real-world evidence. *Journal of Affective Disorders*. 2024;352:199-200. doi:10.1016/j.jad.2024.02.033

Tables

Table 1: Participant demographic, mental health, and psychedelic experience characteristics[a]

Demographic Characteristics	**Session Participants (n=88)**
Age, years (median, range)	43 (22, 79)
Birth sex, No. (%)	
Male	46 (52.0)
Female	41 (46.6)
Gender, No. (%)	
Male	44 (50.0)
Female	40 (45.5)
LGBTQIA+	3 (3.4)
Race[b] , No. (%)	
White	77 (87.5)
American Indian or Alaska Native	1 (1.1)
Mixed/multiple races	3 (3.4)
Ethnicity, No. (%)	
Non-Hispanic/Non-Latinx	77 (87.5)
Hispanic-Latinx	5 (5.7)
Level of education completed, No. (%)	
Graduate or professional degree	31 (35.2)
College or baccalaureate degree	32 (36.4)
Associate's or technical degree	11 (12.5)
High school or some college	13 (14.8)
Employment, No. (%)	
Employed (full-time, part-time, self-employed, or sporadically)	59 (67.1)
Retired	17 (19.3)
Unemployed/on disability	9 (10.2)
Student	1 (1.1)

Annual household income, No. (%)	
⩾ $100,000	30 (34.1)
$50,000-$99,999	25 (28.4)
$10,000-$49,000	18 (20.4)
< $10,000	2 (2.3)
Decline to Answer	13 (14.8)
Residence, No. (%)	
Living in Oregon	47 (53.4)
Living in other U.S. state	40 (45.5)
Living internationally	1 (1.1)
Military veteran, No. (%)	14 (15.9)
Mental Health Characteristics	
Reported mental health diagnosis, No. (%)	
Depression	45 (51.1)
Anxiety	37 (42.0)
PTSD	17 (19.3)
Acute Stress	6 (6.8)
OCD	4 (4.5)
Eating disorder	2 (2.3)
Bipolar disorder[c]	1 (1.1)
Other	6 (6.8)
No mental health diagnosis	32 (36.4)
Currently taking psychiatric medications, No. (%)	41 (46.6)
Currently in therapy, No. (%)	50 (56.8)
Psychedelic Characteristics	
Prior psychedelic experience, No. (%)	57 (64.8)
Barriers to seeking psilocybin services, No. (%)	
Cost	41 (46.6)

Availability	16 (18.2)
Time and schedule	21 (23.9)
Limited knowledge and experience of psychedelics	16 (18.2)
Current support systems in place (or not in place)	6 (6.8)
Legal concerns	4 (4.5)
Judgement from family and peers	4 (4.5)
Current mental health concerns	4 (4.5)
No concerns	28 (31.8)
Other	1 (1.1)

[a] Some categories of characteristics may not add to 100% as some participants declined to answer demographic questions and data are missing. All data is from the screening application, which gathered data at baseline (prior to a psilocybin administration session). Abbreviations: LGBTQIA+, Lesbian, Gay, Bisexual, Transgender, Queer, Intersex, Asexual, all other identities not explicitly mentioned; OCD, obsessive compulsive disorder; PTSD, post-traumatic stress disorder.

[b] Race variable was a “select all that apply” field. Participants who selected more than one race were grouped into a “Mixed / Multiple race” option and custom responses that didn’t match the standard categories were grouped into “Other”.

[c] Participants who listed bipolar disorder as a mental health diagnosis in their screening application were subsequently screened by Bendable. Those who never had a formal diagnosis of bipolar disorder and were otherwise eligible were allowed to continue to a psilocybin session.

Table 2: Participant classification by PHQ-8, GAD-7, and WHO-5 categories pre- and post-psilocybin session[a]

Participant Classification Category	Pre-Session (n=88)	30-days Post-Session (n=88)
PHQ-8 (depression), No. (%)		
Minimal	27 (30.7)	54 (61.4)
Mild-Moderate	45 (51.1)	31 (35.2)
Moderately Severe-Severe	16 (18.1)	3 (3.4)
GAD-7 (anxiety), No. (%)		
Minimal	29 (33.0)	62 (70.5)
Mild-Moderate	44 (50)	25 (28.4)
Severe	15 (17.0)	1 (1.1)
WHO-5 (well-being), No. (%)		
Normal	6 (6.8)	57 (64.8)
Borderline	0 (0)	9 (10.2)
Low-very low	82 (93.2)	22 (25.0)

[a] Participants completed online surveys that contained the 3 mental health questionnaires (PHQ-8, GAD-7, WHO-5) at two timepoints: pre-session and approximately 30-days post-psilocybin administration session. Pre-session surveys were completed, on average, 75 days prior to the psilocybin administration session; 30-day post-session surveys were completed, on average, 34 days after the psilocybin administration session. Abbreviations: GAD-7, Generalized Anxiety Disorder-7; PHQ-8, Patient Health Questionnaire-8; WHO-5, World Health Organization-5 Well-Being index.

Table 3: TPE and psilocybin doses consumed by participants during a legal psilocybin session in Oregon[a]

Dose Type	Dose, mg
TPE dose, mean (SD)	27.8 (8.2)
TPE dose, median (min, max)	29.9 (13.9, 50.2)
Psilocybin dose, mean (SD)	24.3 (8.3)
Psilocybin dose, median (min, max)	22.0 (9.1, 44.6)

[a] TPE, Total Psilocybin Equivalents, is defined as psilocybin (mg) + 1.39 × psilocin (mg). This metric assumes complete conversion of psilocybin to psilocin based on molecular weight.

Figures

Figure 1. Study components within the framework of a legal psilocybin services program in Oregon



Figure 1 Footnote: Study components were integrated into an existing legal psilocybin services program in Oregon, Bendable Therapy. Oregon regulatory minimums require one facilitator-client preparation session 24-hours in advance of a psilocybin administration session and to offer an optional integration session post-administration.[21] The study site psilocybin program included additional comprehensive screening, multiple preparation sessions, and structured integration support sessions with licensed facilitators of which many held additional clinical health licenses. Abbreviations: GAD-7, Generalized Anxiety Disorder-7 questionnaire; HPPD, Hallucinogen Persisting Perception Disorder; PHQ-8, Patient Health Questionnaire-8; iPPS, Imperial Psychedelic Predictor Scale; WHO-5, World Health Organization Well-Being-5 Index.

Figure 2 Title: PHQ-8, GAD-7, and WHO-5 estimated marginal mean scores before and 30-days following a legal psilocybin session in Oregon



Figure 2 Footnote: Scores from the PHQ-8 (depression), GAD-7 (anxiety), and WHO-5 (well-being) questionnaires are represented as estimated marginal means with error bars indicating standard errors. Adjusted linear mixed effects models evaluated change in outcomes, with all models significant at $p<0.001$. Score data were collected from surveys emailed to participants prior to a psilocybin session (completed on average 75 days before the session) and approximately 30-days after the psilocybin session (completed on average 34 days post-session). Abbreviations: GAD-7, Generalized Anxiety Disorder-7; PHQ-8, Patient Health Questionnaire-8; WHO-5, World Health Organization Well-Being Index-5.